Dilated Cardiomyopathy - Pipeline Review, H2 2020
Dilated Cardiomyopathy - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2020, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.
Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2020, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.
Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Dilated Cardiomyopathy - Therapeutics Assessment
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Dilated Cardiomyopathy - Drug Profiles
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Appendix
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Dilated Cardiomyopathy - Therapeutics Assessment
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Dilated Cardiomyopathy - Drug Profiles
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Dilated Cardiomyopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Dilated Cardiomyopathy - Pipeline by Berlin Cures Holding AG, H2 2020
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H2 2020
Dilated Cardiomyopathy - Pipeline by CellServe GmbH, H2 2020
Dilated Cardiomyopathy - Pipeline by Heartseed Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Help Therapeutics, H2 2020
Dilated Cardiomyopathy - Pipeline by iHeart Japan Corp, H2 2020
Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Olagenesis Corp, H2 2020
Dilated Cardiomyopathy - Pipeline by Pfizer Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Renovacor Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Shionogi & Co Ltd, H2 2020
Dilated Cardiomyopathy - Dormant Projects, H2 2020
Number of Products under Development for Dilated Cardiomyopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Dilated Cardiomyopathy - Pipeline by Berlin Cures Holding AG, H2 2020
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H2 2020
Dilated Cardiomyopathy - Pipeline by CellServe GmbH, H2 2020
Dilated Cardiomyopathy - Pipeline by Heartseed Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Help Therapeutics, H2 2020
Dilated Cardiomyopathy - Pipeline by iHeart Japan Corp, H2 2020
Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Olagenesis Corp, H2 2020
Dilated Cardiomyopathy - Pipeline by Pfizer Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Renovacor Inc, H2 2020
Dilated Cardiomyopathy - Pipeline by Shionogi & Co Ltd, H2 2020
Dilated Cardiomyopathy - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Dilated Cardiomyopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Berlin Cures Holding AG
Celixir Ltd
CellServe GmbH
Heartseed Inc
Help Therapeutics
iHeart Japan Corp
Martin Pharmaceuticals Inc
MyoKardia Inc
Olagenesis Corp
Pfizer Inc
Renovacor Inc
Shionogi & Co Ltd
Number of Products under Development for Dilated Cardiomyopathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Berlin Cures Holding AG
Celixir Ltd
CellServe GmbH
Heartseed Inc
Help Therapeutics
iHeart Japan Corp
Martin Pharmaceuticals Inc
MyoKardia Inc
Olagenesis Corp
Pfizer Inc
Renovacor Inc
Shionogi & Co Ltd
